ArticleMicromachines2025
A 3D-Printed PMMA Microneedle-Based TSA-ELISA Platform for Noninvasive Inflammatory Biomarker Detection.
Article in Micromachines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Inflammatory cytokines and proteins are essential indicators of immune status and disease progression; however, conventional assays rely on invasive sampling and complex processing, restricting their use in real-time monitoring. Here, we present a 3D-printed poly(methyl methacrylate) (PMMA) microneedle-based biosensing platform integrated with a tyramide signal amplification-enhanced enzyme-linked immunosorbent assay (TSA-ELISA) for noninvasive and highly sensitive detection of inflammatory biomarkers in interstitial fluid. The microneedles exhibit precise geometry, adequate mechanical strength, and excellent biocompatibility, facilitating efficient skin penetration and biomarker capture. Stepwise chemical functionalization ensured stable antibody immobilization, while TSA significantly amplified detection signals. The platform achieved reliable, reproducible, and multiplex detection of cytokines and albumin in both healthy individuals and patients with inflammatory skin conditions. Notably, the measured cytokine level in lesional skin of eczema patients was 97.7 pg/mL, showing a significant difference from the 62.8 pg/mL observed in healthy subjects. This MN-based TSA-ELISA system offers a robust and minimally invasive strategy for monitoring inflammation-related biomarkers, holding great potential for clinical diagnostics and personalized healthcare applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.